logo
logo
LMAT stock ticker logo

LeMaitre Vascular, Inc.

NASDAQ•LMAT
CEO: Mr. George W. LeMaitre
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2006-10-19
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
連絡先情報
63 Second Avenue, Burlington, MA, 01803, United States
781-221-2266
www.lemaitre.com
時価総額
$2.45B
PER (TTM)
42.2
58.7
配当利回り
0.7%
52週高値
$115.33
52週安値
$71.42
52週レンジ
82%
順位23Top 9.4%
5.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$64.45M+0.00%
直近4四半期の推移

EPS

$0.69+0.00%
直近4四半期の推移

フリーCF

$21.38M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Sales Growth 14% Net sales reached $249.6M USD, marking a 14% increase driven by higher average selling prices and unit volumes.
Gross Margin Expansion Gross profit grew 18% to $178.5M USD; margin improved 290 basis points to 71.5% aided by ERC receipt.
Strong Operating Cash Flow Cash provided by operations was $81.3M USD, a significant increase from $44.1M USD reported in the prior year.
Dividend Rate Increased Board approved $0.25 per share dividend in Feb 2026, up from $0.20 per share paid quarterly throughout 2025.

リスク要因

Profit Growth Sustainability Historical operating income growth drivers like pricing increases may slow or disappear if favorable factors are not replicated.
Supply Chain Reliance Risk Dependence on sole or limited-source suppliers for critical components, including biologic and tissue-based products, exposes production.
Cybersecurity Incident Exposure Experienced a cybersecurity incident in January 2026; ongoing investigation may result in future liability or operational disruption.
Regulatory Approval Hurdles Failure to obtain and maintain regulatory clearances in various geographies could limit ability to sell products and hamper growth.

見通し

Direct Sales Force Expansion Intend to further expand direct sales force, which comprised 160 representatives at year-end 2025, to penetrate new markets.
Acquisition Growth Strategy Will continue using acquisitions as primary means to penetrate peripheral vascular device market segments and add complementary products.
Manufacturing Consolidation Timeline Transferring majority of allograft tissue processing operations from Fox River Grove to Burlington facility, expected completion by end of 2026.
Share Repurchase Authorization Board authorized $100.0M USD share repurchase program through February 2027 to return capital to common stockholders.

同業比較

売上高 (TTM)

ARDT stock ticker logoARDT
$6.32B
+6.0%
ACHC stock ticker logoACHC
$3.31B
+5.0%
QDEL stock ticker logoQDEL
$2.73B
-1.9%

粗利益率 (最新四半期)

STOK stock ticker logoSTOK
90.7%
-9.3pp
INSP stock ticker logoINSP
86.6%
+1.8pp
ATRC stock ticker logoATRC
74.4%
+0.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
HAE$3.00B17.120.3%49.2%
TWST$2.88B-37.4-16.6%28.8%
NHC$2.60B21.611.6%5.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.5%
緩やかな成長
4四半期純利益CAGR
12.3%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし